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aid clinicians when advising patients and their caregivers
about prognosis and treatment.
PMH3
ANTIPSYCHOTIC AGENTS AND THE RISK OF
DEVELOPING DIABETES
Caro JJ1,Ward A1, Levinton C1, Robinson K2
1Caro Research Institute, Concord, MA, USA; 2Janssen-Ortho
Inc,Toronto, ON, Canada
OBJECTIVES: To assess the risk of diabetes among
patients undergoing treatment with risperidone vs.
haloperidol. A series of case reports had associated some
antipsychotic agents with diabetes.
METHODS: Patients with at least one prescription 
for either haloperidol or risperidone between January
1997 and 31st December 1999 recorded in the Regie de
l’Assurance Maladie de Quebec database, excluding 
those dispensed clozapine or olanzapine during the study
period or diagnosed with diabetes (deﬁned as either a
recorded ICD9 250.0 to 250.93 or a prescription for
insulin or an oral hypoglycemic agent) before beginning
anti-psychotic therapy, were divided into haloperidol
recipients (N = 14,602) and those receiving risperidone
but not haloperidol (N = 9,961). New diabetes diagnoses
after the ﬁrst antipsychotic prescription were tabulated;
censoring at study end or the last service date if there was
no record of using any services during the last six months
of follow-up. Crude hazard ratios and proportional
hazards analyses were carried out.
RESULTS: 406 patients developed diabetes after being
prescribed haloperidol, and 123 after risperidone, a crude
hazard ratio of 2.29 (95% CI 1.81–2.90). When correct-
ing for imbalances in age, and gender, using proportional
hazards analysis, haloperidol still increased the risk of
diabetes by 93% (HR = 1.93, 95% CI 1.57–2.37, 
P < 0.0001). Correction for other imbalances did not
change the ﬁndings.
CONCLUSIONS: Haloperidol was associated with an
increased risk of developing diabetes compared to risperi-
done. Additional studies are required to identify a bio-
logical basis for this association, and to examine other
atypical antipsychotics to determine which have the
lowest risk of diabetes.
PMH4
SUPPLEMENTAL ANALYSIS OF THE
QUETIAPINE EXPERIENCE WITH SAFETY AND
TOLERABILITY (QUEST) STUDY
White R1, Simons WR2,Yu E1
1AstraZeneca, Wilmington, DE, USA; 2Global Health
Economics & Outcomes Research, Inc, Summit, NJ, USA
OBJECTIVE: To assess whether a 5-factor instead of 
3-factor model more completely describes the range of
psychotic symptoms as measured by the Positive and Neg-
ative Syndrome Scale (PANSS) with data from the Que-
tiapine Experience with Safety and Tolerability (QUEST)
trial, and to reevaluate the comparative efﬁcacy of queti-
apine and risperidone using the 5-symptom model.
METHODS: We used exploratory factor analysis (EFA)
to test whether three factors adequately describe symp-
toms as measured by the PANSS or if more factors are
needed. The initial EFA is carried out using only baseline
data. Evaluating the test for breaks in eigen values deter-
mines the number of factors. We used the n-factor rule to
retain and rotate enough factors to explain 99% of the
variation. Using the derived factorial structure, we per-
formed comparative analyses on the intent-to-treat (ITT)
population and on patients with clinically signiﬁcant
baseline symptoms (CSBS) at 2 and 4 months.
RESULTS: 554 patients had completed PANSS data; 
5 factors explained 99.9% of data variance and labeled
negative, positive, activation, dysphoria, and autistic pre-
occupation symptoms with corresponding eigen values
28.97, 7.55, 3.59, 2.63 and 1.45 explaining 66%, 17%,
8%, 6%, and 3% of the variation. Statistical analyses
found that, compared with risperidone, quetiapine con-
sistently improves dysphoria sooner and in patients with
CSBS. At 2 months quetiapine-treated patients’ absolute
change from baseline was -3.11 compared to -2.22 (P =
0.03). For patients with clinically signiﬁcant baseline 
negative symptoms, at 2-months the comparative change
in dsyphoria was -3.79 vs. -2.34 (P = 0.02). In patients
with clinically signiﬁcant positive symptoms, quetiapine
improved dsyphoria symptoms better than risperidone at
2 and 4-months, -4.06 vs. -2.24 (P = 0.01) and -4.73 vs.
-2.88 (P = 0.03).
CONCLUSIONS: PANSS is more completely described
with ﬁve symptoms. Compared with risperidone, queti-
apine displays clinical advantage in improving dysphoria
not evident when a 3-factor model is used.
PMH5
EFFICACY OF NURSE TELEHEALTH CARE AND
PEER SUPPORT IN AUGMENTING TREATMENT
OF DEPRESSION IN PRIMARY CARE
Hunkeler EM1, Meresman JF2, Heargreaves WA3
1Kaiser Permanente, Oakland, CA, USA; 2Kaiser Permanente,
Northern California, Santa Clara, CA, USA; 3University of
California, San Francisco, San Francisco, CA, USA
OBJECTIVES: Because clinical outcomes depression
treatment in primary care settings tend to be poor, we
developed and evaluated the efﬁcacy of two augmenta-
tions to antidepressant treatment to be delivered by
primary care nurses.
METHODS: We conducted a randomized trial compar-
ing usual care, telehealth care, and telehealth care plus
peer support for depressed patients seen in primary care
in an HMO setting. Assessments were conducted at base-
line, 6 weeks and 6 months after study enrollment at two
managed care adult primary care clinics. Participants
were 303 patients recently started on antidepressants. The
intervention consisted of: telehealth care; emotional
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support and focused behavioral interventions in 10 7-
minute calls over four months by specially trained
primary care nurses and peer support; telephone and 
in-person supportive contacts by trained Health Plan
members recovered from depression. Primary outcome
measures were the Hamilton Rating Scale for Depression,
Beck Depression Inventory, Mental and Physical Func-
tioning, Short Form 12, and treatment satisfaction and
medication adherence questionnaires.
RESULTS: Nurse-based telehealth patients with or
without peer support more often experienced 50%
improvement on the Hamilton at 6 weeks (50% vs. 37%,
P = .01) and 6 months (57% vs. 38%, P = .003), and on
the Beck at 6 months (48% vs. 37%, P = .05), and greater
quantitative reduction in symptom scores on the 
Hamilton at 6 months (10.4 vs. 8.1, P = .006). Telehealth
care improved mental functioning at 6 weeks (47.1 vs.
42.6, P = .004) and treatment satisfaction at 6 weeks
(4.41 vs. 4.17, P = .004) and 6 months (4.20 vs. 3.94, P
= .001). Medication adherence was the same in all groups,
and adding peer support to telehealth care did not
improve the main outcomes.
CONCLUSION: Nurse Telehealth Care improves clinical
outcomes of antidepressant treatment, improves patient
satisfaction, and ﬁts well in primary care. The nurse tele-
care program has been implemented in Maine, Ohio and
Southern California.
PMH6
RISK OF DIABETES FOR INDIVIDUALS WITH
SCHIZOPHRENIA TREATED WITH
ANTIPSYCHOTICS
Zhao Z, Loosbrock DL
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To assess the incidence of diabetes 
for individuals with schizophrenia treated with 
antipsychotics.
METHODS: Retrospective analysis of a large, geo-
graphically diverse claims database of insured individuals
identiﬁed 815 enrollees aged 18 to 64 who: (1) were diag-
nosed with schizophrenia; (2) were initiated on typical 
(n = 353) or atypical (n = 462) antipsychotics between
October 1, 1996 and December 31, 1998; (3) had no use
of any antipsychotics six-month prior-initiation; and (4)
had no diagnosis of diabetes and/or no use of antidia-
betics in the year prior. New onset diabetes was deﬁned
as either two diagnoses for diabetes (ICD9 250.xx) or
prescription for antidiabetics in the year post-initiation.
Logistic regressions were used to compare the odds of
incidence of diabetes, controlling for demographics and
prior-medical comorbidities.
RESULTS: The probability of becoming diabetic was 
not signiﬁcantly different for atypical cohort compared to
typical cohort (odds ratio = 2.533; p = 0.088) or for olan-
zapine cohort versus typical cohort (odds ratio = 1.093,
p = 0.900). Risperidone-treated patients had signiﬁcantly
higher incidence of diabetes compared to those treated
with typicals (odds ratio = 4.362, p = 0.016). Olanzap-
ine compared to risperidone cohort was associated with
a signiﬁcantly lower incidence of diabetes (odds ratio =
0.277, p = 0.050).
CONCLUSIONS: The incidence of diabetes was similar
for individuals with schizophrenia receiving treatment
with atypical compared to typical antipsychotic agents.
Additionally, individuals receiving treatment with olan-
zapine compared to risperidone had a lower incidence of
diabetes.
PMH7
OUTCOMES AND COST OF TREATMENT WITH
RISPERIDONE VERSUS OLANZAPINE AMONG
PATIENTS WITH CHRONIC SCHIZOPHRENIA
OR SCHIZOAFFECTIVE DISORDERS
Vera-Llonch M1, Oster G1, Delea T1, Rupnow M2, Grogg A2
1Policy Analysis Inc, Brookline, MA, USA; 2Janssen
Pharmaceutica Products, L.P,Titusville, NJ, USA
OBJECTIVES: To estimate clinical outcomes and 
associated cost of care of treatment with risperidone
versus olanzapine in patients with chronic schizophrenia
or schizoaffective disorders up to one year following
therapy initiation.
METHODS: A Markov model was developed to estimate
the number of patients who experience side effects 
(i.e., extrapyramidal symptoms [EPS], prolactin-related
disorders, weight gain, and diabetes) of antipsychotic
therapies, relapse of psychiatric symptoms as well as dis-
continuation of antipsychotic therapy following these
events at one year; associated costs of care were also cal-
culated. Parameter estimates were based on ﬁndings from
a randomized, controlled, clinical trial of risperidone and
olanzapine and other published and unpublished sources.
Analyses were undertaken using second-order Monte
Carlo simulation techniques with 10,000 individual
trials.
RESULTS: The expected number of patients remaining
on initial therapy at one year was higher for risperidone
(76.3% versus 44.7% for olanzapine); the expected
number of months on therapy was lower for olanzapine
(8.0 vs. 10.5 for risperidone). Therapy discontinuation
was primarily driven by patients experiencing increases 
in body weight exceeding 5kg since therapy initiation.
Expected mean total costs per month on therapy were 8%
higher for olanzapine ($2,198 vs. $2,033 for risperidone).
CONCLUSIONS: Therapy discontinuation at one year
was lower for risperidone than for olanzapine. Expected
costs of care per month of therapy were also lower.
